Skip to content
wua. United Kingdom English

UHCW chemotherapy review: why an apology cannot close the case

AI-generated editorial illustration; this is not a photograph of the event.
Produced by wua.life

The Royal College of Physicians' review has turned complaints about long-term chemotherapy at University Hospitals Coventry and Warwickshire NHS Trust into a clear patient-safety and accountability issue. It examined 20 cases under the care of retired clinical oncologist Prof Ian Brown and found repeated, extended temozolomide treatment that was contrary to standard practice and national guidelines.

The immediate scale is larger than those 20 files. The review said 83 people received extended TMZ treatment between 2017 and 2023 and warned that further patients may have been affected. TMZ is generally given after radiotherapy for six cycles, usually over about six months, according to the BBC's report. The RCP described a potentially large cohort of deceased patients who received the non-standard regimen and said the trust should consider whether a wider review is appropriate, in discussion with the Department of Health and Social Care and/or NHS England.

That leaves two decisions that an apology cannot settle. First, UHCW must decide whether and how to review the wider group, including deceased patients. Second, ministers and NHS England may need to decide whether the circumstances warrant the public inquiry sought by patients. Neither step has been announced in the material reported by the BBC.

UHCW has apologised for failures in its neuro-oncology service, with its chief executive and chair saying the standard of care was far below what patients deserved. That acknowledgement matters, but it is not a substitute for a defined process to identify affected people, examine the scope of harm and explain who will oversee any broader review.

Prof Brown retired in 2024, did not take part in the RCP review and declined to comment when approached by the BBC. The review's findings do not by themselves determine individual legal or clinical responsibility. But they do make the case for transparent next decisions stronger: patients should not have to rely on separate legal claims to learn whether the system will examine the full consequences of a practice found to have departed from national guidance.

Sources

Independent editorial content. WUA is not affiliated with any political party. 2026-11-18